Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,311

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

Open access
Bisogno, Tiziana, Hanuš, Lumír, De Petrocellis, Luciano, Tchilibon, Susanna, Ponde, Datta E, Brandi, Ines, Moriello, Aniello Schiano, Davis, John B, Mechoulam, Raphael, Di Marzo, Vincenzo·2001·British Journal of Pharmacology
DOI 10.1038/sj.bjp.0704327
Open this paper in CoChat — free account

Abstract

(−)‐Cannabidiol (CBD) is a non‐psychotropic component of Cannabis with possible therapeutic use as an anti‐inflammatory drug. Little is known on the possible molecular targets of this compound. We investigated whether CBD and some of its derivatives interact with vanilloid receptor type 1 (VR1), the receptor for capsaicin, or with proteins that inactivate the endogenous cannabinoid, anandamide (AEA). CBD and its enantiomer, (+)‐CBD, together with seven analogues, obtained by exchanging the C‐7 methyl group of CBD with a hydroxy‐methyl or a carboxyl function and/or the C‐5′ pentyl group with a di‐methyl‐heptyl (DMH) group, were tested on: (a) VR1‐mediated increase in cytosolic Ca 2+ concentrations in cells over‐expressing human VR1; (b) [14 C]‐AEA uptake by RBL‐2H3 cells, which is facilitated by a selective membrane transporter; and (c) [14 C]‐AEA hydrolysis by rat brain membranes, which is catalysed by the fatty acid amide hydrolase. Both CBD and (+)‐CBD, but not the other analogues, stimulated VR1 with EC 50=3.2 – 3.5 μ M, and with a maximal effect similar in efficacy to that of capsaicin, i.e. 67 – 70% of the effect obtained with ionomycin (4 μ M). CBD (10 μ M) desensitized VR1 to the action of capsaicin. The effects of maximal doses of the two compounds were not additive. (+)‐5′‐DMH‐CBD and (+)‐7‐hydroxy‐5′‐DMH‐CBD inhibited [14 C]‐AEA uptake (IC 50=10.0 and 7.0 μ M); the (−)‐enantiomers were slightly less active (IC 50=14.0 and 12.5 μ M). CBD and (+)‐CBD were also active (IC 50=22.0 and 17.0 μ M). CBD (IC 50=27.5 μ M), (+)‐CBD (IC 50=63.5 μ M) and (−)‐7‐hydroxy‐CBD (IC 50=34 μ M), but not the other analogues (IC 50>100 μ M), weakly inhibited [14 C]‐AEA hydrolysis. Only the (+)‐isomers exhibited high affinity for CB 1 and/or CB 2 cannabinoid receptors. These findings suggest that VR1 receptors, or increased levels of endogenous AEA, might mediate some of the pharmacological effects of CBD and its analogues. In view of the facile high yield synthesis, and the weak affinity for CB 1 and CB 2 receptors, (−)‐5′‐DMH‐CBD represents a valuable candidate for further investigation as inhibitor of AEA uptake and a possible new therapeutic agent. British Journal of Pharmacology (2001) 134, 845–852; doi:10.1038/sj.bjp.0704327

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0704327

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2001-10
Volume
134
Issue
4
Pages
845-852
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
DOI
10.1038/sj.bjp.0704327
OpenAlex
W2030623240
Cited by
1,311
References
6
FWCI
16.97
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.